Vericel Denmark ApS: Financial statements 2013
CVR: 19740986
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
Vericel Denmark ApS (CVR 19740986) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 55,064,189 and a net result of DKK -4,215,411 compared with DKK 3,694,770 the year before. That is an increase of 134.1% compared with the year before. Equity in the 2013 report amounted to DKK 32,991,004. The solvency ratio was 71.3%.
- Gross Profit
- DKK 55,064,189
- Profit/Loss
- DKK -4,215,411
- Equity
- DKK 32,991,004
- Total Assets
- DKK 46,251,108
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2013 | - | 55.1 mio. | -4.2 mio. | 33 mio. | - |
| 2012 | - | 23.5 mio. | 3.7 mio. | 37.2 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
Vericel Denmark ApS has published its annual report for 2012. Gross profit came to DKK 23,522,506, and the net result was DKK 3,694,770.
About Vericel Denmark ApS
Vericel Denmark ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 1996. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named AASTROM BIOSCIENCES DK ApS and GENZYME BIOSURGERY ApS. The management consists of Joseph Anthony Mara Jr. The company is owned by Vericel Corporation. The company has 0 employees (2015). In 2025, the company reported a gross profit of DKK -128,481 and a net result of DKK -128,481 compared with DKK -109,464 the year before. Equity in the 2025 report amounted to DKK 6,241,335.